After testicular cancer treatment, most men are cured. The five-year survival rate exceeds 95%, making it one of the most treatable cancers. But “cured” doesn’t mean “done.” What follows is years of structured monitoring, physical recovery, and attention to long-term health risks that can surface months or even decades later. Here’s what that looks like in practice.
The Follow-Up Schedule
Once initial treatment is complete, you enter a surveillance period designed to catch any recurrence early. For stage I nonseminoma, the schedule is intensive at first: monthly visits during the first year, every two months in year two, every three months in year three, tapering to every six months by year five, and then annually for another five years. Each visit typically includes a physical exam, blood tests to check tumor markers, and a chest X-ray.
Seminoma follow-up is slightly different, with visits roughly every four months for the first three years, then every six months for three more years, and annually after that. Both types include periodic CT scans of the abdomen to check for cancer in the lymph nodes, though exactly how often those scans should happen is still debated among specialists. Some guidelines call for scans every three to four months in the first few years, while others take a more conservative approach to limit radiation exposure.
Recurrence Risk
For stage I seminoma on surveillance (no additional treatment after surgery), about 14 to 20% of men will experience a relapse, most within the first three years. The risk depends partly on tumor size: a 1 cm tumor carries roughly a 9% chance of relapse at three years, while an 8 cm tumor raises that to about 26%. The five-year relapse-free rate sits around 85% overall.
If cancer does come back, it’s still highly treatable. Recurrences caught through surveillance are typically managed with chemotherapy or radiation, and cure rates remain very high even after relapse. This is why the monitoring schedule is so front-loaded in those early years.
Recovering From Surgery
If you’ve had an orchiectomy (removal of one testicle), the physical recovery is relatively quick. Most men return to normal activities within a few weeks. The bigger recovery challenge comes with retroperitoneal lymph node dissection, or RPLND, a surgery to remove lymph nodes from the back of the abdomen. This involves a large incision along the length of the abdomen, a hospital stay of three to five days, and a recovery period of two to four weeks before you feel fully yourself again.
After RPLND, your surgical team may put you on a temporary low-fat diet. The surgery disrupts lymphatic channels in the abdomen, and fatty foods can trigger lymphatic fluid leaks. A nutritionist will guide you on gradually returning to a normal diet over the following weeks.
Fertility After Treatment
Chemotherapy and radiation both suppress sperm production, but for most men, it recovers. About 81% of men see sperm production return after treatment, with a median recovery time of roughly two to two and a half years. At the two-year mark, only about 3% of men who received chemotherapy and 6% who received radiation still have no detectable sperm.
The picture changes with more aggressive treatment. After four cycles of platinum-based chemotherapy, only about 25% of men recover sperm production within three years, rising to 45% by five years. This is why sperm banking before treatment begins is so strongly recommended, especially for men who haven’t yet started families.
RPLND introduces a separate fertility concern: retrograde ejaculation, where semen flows backward into the bladder instead of out through the penis. This happens when the surgery damages sympathetic nerves that control the bladder neck. Nerve-sparing surgical techniques reduce this risk, but when it does occur, treatment options are limited. Medications that increase the muscle tone of the bladder neck help in some cases, with combination drug therapy achieving about a 39% success rate. When medication doesn’t work, sperm can be retrieved from post-ejaculatory urine or directly from the testes for use in assisted reproduction.
Testosterone and Hormonal Changes
Losing one testicle doesn’t automatically mean low testosterone. The remaining testicle usually compensates. In one large study following patients for more than five years, about 11% of men who had an orchiectomy alone developed low testosterone levels. That rate climbed to 37% for men who received both radiation and chemotherapy, since these treatments can damage the remaining testicle’s hormone-producing cells.
Low testosterone can show up as fatigue, reduced sex drive, difficulty concentrating, loss of muscle mass, and mood changes. If blood tests confirm deficiency, testosterone replacement therapy can effectively manage these symptoms. It’s worth having your levels checked periodically during follow-up, especially if you notice any of these changes.
Cardiovascular and Metabolic Risks
This is one of the less well-known consequences of testicular cancer treatment, and one of the most important. Survivors face a dramatically elevated risk of metabolic syndrome, a cluster of conditions including high blood pressure, high blood sugar, excess abdominal fat, and abnormal cholesterol. In one large study, the five-year rate of new metabolic syndrome was 17% among testicular cancer survivors compared to just 1.9% in matched controls. By ten years, it reached 27.8% versus 2.8%.
This matters because metabolic syndrome is a direct pathway to heart disease, and cardiovascular problems are a recognized cause of late mortality in cancer survivors. Staying physically active, maintaining a healthy weight, and having regular checkups that include blood pressure, cholesterol, and blood sugar monitoring are practical steps that can meaningfully reduce this risk.
Secondary Cancers
Treatment for testicular cancer, particularly radiation and chemotherapy, slightly increases the risk of developing a different cancer later in life. Overall, the risk of a second primary cancer is about 30% higher than in the general population. That risk grows with more treatment: radiation roughly doubles the risk at around 17 years of follow-up, and receiving multiple lines of treatment raises it nearly fourfold.
The most elevated risks involve kidney, thyroid, and soft tissue cancers (three to seven times higher), along with certain blood cancers. Acute myeloid leukemia risk is about 3.6 times higher, linked specifically to the combination of drugs used in standard testicular cancer chemotherapy. These are still relatively rare cancers, so a 3.6-fold increase of a small number remains a small number. But it’s a reason to stay engaged with your follow-up care and mention any new or unusual symptoms to your doctor, even years after treatment ends.
Mental Health After Treatment
The emotional toll of testicular cancer doesn’t end when treatment does. Within five years, over half of testicular cancer survivors experience anxiety or depression, compared to about 35% in the general population. Among men with no prior mental health history, 30% develop new anxiety or depression after their cancer diagnosis, roughly double the rate of their peers.
Fear of recurrence is a major driver, affecting about 30% of survivors. The intensive follow-up schedule can paradoxically feed this anxiety: each scan or blood test becomes a moment of dread. The five-year rate of suicidal thoughts or behaviors, while still low in absolute terms, is significantly higher among survivors (5%) than controls (0.1%).
These aren’t signs of weakness. They’re predictable consequences of going through cancer at what is often a young age. Therapy, peer support groups specifically for young adult cancer survivors, and in some cases medication can all help. If you notice persistent changes in mood, sleep, or motivation after treatment, it’s worth addressing directly rather than waiting for it to resolve on its own.